ArticlePulmonary medicine2012
Role of talc modulation on cytokine activation in cancer patients undergoing pleurodesis.
Article in Pulmonary medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Progress in Mechanistic Research and the Use of Traditional Chinese Medicine in Treating Malignant Pleural Effusion.Cancer management and research · 2025Review
- Impact of Factors Secreted by Tumor Cells on Response of Pleural Mesothelial Cells to Different Sclerosing Agents in an In Vitro Model.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Primary human mesothelial cell culture in the evaluation of the inflammatory response to different sclerosing agents used for pleurodesis.Physiological reports · 2021Article
- Chemical pleurodesis - a review of mechanisms involved in pleural space obliteration.Respiratory research · 2019Review
- Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study.Wiener klinische Wochenschrift · 2015Article
- Management of malignant pleural effusion.Lung · 2013Review
- Systemic Inflammatory Response to Different Sclerosing Agents as a Predictor of Pleurodesis Outcome.In vivo (Athens, Greece)Article
- Clinical outcomes of chemical pleurodesis using a minocycline.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigate the mechanism of talc pleurodesis (TP) in 20 patients with recurrent malignant pleural effusion and 10 patients with nonmalignant pleural effusions. We measured IL-8 levels before and 6 h after TP and find a significant threefold increase (2.26 ng/mL ± 0.7 to 6.5 ng/mL 0.1), which explains the recruitment of inflammatory cells in these patients. We hypothesize that TP is enable by stimulating the mesothelial cells (MS) to secrete FGF. A significant tenfold increase in FGF-b (0.05 ng/mL ± 0.02 to 0.44 ng/mL 0.6) was seen 24 h after talc instillation (P < 0.04). In order to examine whether FGF-b is secreted by MS cells, MS recovered from CHF patients with recurrent pleural effusions were cultured for 48 h in the presence or absence of increasing concentrations of talc (from 100 ng/mL to 1 mg/mL). They produced significant levels of FGF-b in a dose dependent manner (P < 0.005). We hypothesized that a successful pleurodesis involves an early enhanced recruitment of inflammatory cells through a rise of IL-8 followed by enrollment of fibroblasts from the submesothelial space through increased mesothelial FGF-b production.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.